Bedaquiline

Chemical formula: C₃₂H₃₁BrN₂O₂ Molecular mass: 555.505 g/mol PubChem compound: 5388906

Therapeutic indications

Bedaquiline is indicated for:

Multidrug-resistant tuberculosis (MDR-TB)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

400 mg once daily at weeks 1-2 and thereafter 200 mg once daily three times per week at weeks 3-24

160-400 mg once daily at weeks 1-2 and thereafter 80-200 mg three times per week at weeks 3-24

Contraindications

Bedaquiline is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.